Roche Holding AG
ROP
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
112,774
Roche Holding AG News & Analysis
personal-finance
The US dollar looks overvalued. Should individual investors care?
Some things are a lot more important to professional investors than everybody else.
stocks
3 cheap Wide Moat stocks in a divided industry
All but a couple of shares in this industry have sold off. Our analysts think these three high quality companies have fallen too far.
stocks
Obesity drug stocks: Where to invest now
Eli Lilly and Novo Nordisk have staged big rallies. Here’s how investors can approach this potentially huge opportunity.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,903.50 | 44.30 | 0.50% |
| CAC 40 | 7,870.40 | 36.30 | 0.46% |
| DAX 40 | 25,464.37 | 210.16 | 0.83% |
| Dow JONES (US) | 51,647.96 | 380.06 | 0.74% |
| FTSE 100 | 10,540.26 | 42.32 | 0.40% |
| HKSE | 24,280.56 | 240.22 | 1.00% |
| NASDAQ | 27,721.67 | 244.36 | 0.89% |
| Nikkei 225 | 70,683.98 | 737.12 | 1.05% |
| NZX 50 Index | 13,700.12 | 1.10 | 0.01% |
| S&P 500 | 7,842.18 | 68.23 | 0.88% |
| S&P/ASX 200 | 8,735.70 | 49.30 | 0.57% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |